The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Alzheimer's disease, a relentless condition that steals memory and independence, now has a powerful new opponent: donanemab ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

The newly approved test, developed by Fujirebio Diagnostics, Inc., is designed for patients aged 55 and older who are ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Four South Florida sites are enrolling people with memory loss into a national trial for benfotiamine, a lab-made vitamin ...

LEXINGTON For the past four decades, the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) has been at the ...

For the past four decades, the University of Kentucky’s Sanders-Brown Center on Aging has been at the forefront of Alzheimer’s disease research, making groundbreaking discoveries that have shaped expe ...